4D-Nucleofector® LV Unit
4D-Nucleofector® LV Unit
For closed, scalable large-scale transfection of up to 1x109 cells.
Product Overview
Large-Scale Transfection Using the 4D-Nucleofector® LV Unit - Experience the latest functional unit for the 4D-Nucleofector® System which expands our proven system to larger-scale transfection.
The LV Unit allows for closed, scalable transfection of larger cell numbers in the range of 1x107 to 1x109 cells. Transfection protocols can be established in smaller scale using the X Unit and subsequently transferred to the LV Unit without the need for re-optimization. Transferability has been tested for various cell types, including human T cells, CHO-S, HEK293-S, or K-562.
Accompanied by GMP grade TheraPEAK® Consumables, a 21CFR part 11 compliant software and IQOQ services the LV Unit is suited to quickly translate research results into a GMP compliant manufacturing process.
There are cell type-specific Optimized Protocols or recommendations available in our knowledge database. In these Optimized Protocols the best Nucleofection conditions are indicated. In addition, we share our experience and knowledge for treatment of individual cell types.
Technical Specifications
Dimensions: (w x h x d): 24.5×20.7×28 cm / 9.7×4.1×11.0
Weight: 5.7 kg (12.5 lb)
Power: 100 - 240 VAC
Frequency: 50 - 60 Hz
Consumption: 0 VA (power off) / 20 VA (idle) / 140 VA (busy - during transfection)
Fuse: T 2.5A, L250V
Operating temperature: +15°C up to +40°C (59°F - 104°F)
Environment non condensing voltage limitation: 1500 V
Current limitation: 100 A
Quality statement:
We are applying ISO 9001:2015 standards for the design, manufacturing and testing of Nucleofector® Devices since 2004.
* TheraPEAK® Nucleofector® Products are produced according to applicable GMP raw material standards and are intended to support GMP manufacturing. TheraPEAK® Nucleofector® Solutions are manufactured at a GMP certified site. TheraPEAK® Nucleofector® Cartridges and Reservoirs are produced at manufacturing sites with an ISO13485 certified quality management system. TheraPEAK® Nucleofector® Products are not intended for in vivo and/or diagnostic purposes. All other Nucleofector® Products are for research use only.
Request More Info
Benefits
- Closed system: Sterile Nucleofection of up to 109 cells
- Real scalability: Optimization in small scale
- Established protocols: Benefit from 700+ optimized cell types
- Simple handling: Minimal training needs
- 4D-Nucleofector® LogWare: Optional operation via 21CFR part11 compliant software
- Fit for purpose: Consumables for research use and GMP manufacturing*
Applications
- Ex-vivo modification of human primary cells for cell therapy applications (e.g. genome editing, generation of CAR-T cells)
- Transient production of potential therapeutic proteins or antibodies for construct screening
- Generation of large numbers of transiently modified primary cells for cell-based assays
Storage and Content
1 UnitSDS, CoA, and Instructions
Safety Data Sheets (SDS)
SDS not applicable
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
-
Transfection Protocol (General) - 4D-Nucleofector™ LV Unit
General instructions of use for transfection with the 4D-Nucleofector™ LV Unit -
Important Vector Factors for Gene Expression – Technical Reference Guide
In this guideline, we show the most important aspects to be considered when choosing an expression vector and their impact on your experimental results. -
Nucleofector® Technology Brochure
Stretching Transfection Dimensions -
4D-Nucleofector™ Manual
Comprises instructions for all units (Core, X, Y and LV Unit). -
4D-Nucleofector® Hardware Manual
Manual for next generation 4D-Nucleofector Core, X, Y, 96-well, and LV Unit Vers.1
Educational Material
Brochures, White Papers etc.
Videos
-
Important Vector Factors for Gene Expression – Technical Reference Guide
In this guideline, we show the most important aspects to be considered when choosing an expression vector and their impact on your experimental results. -
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cells
A strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells. -
A Non-Viral Method for Modifying and Expanding Primary T Cells
Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow. -
4D-Nucleofector® LV Unit for Large-scale Transfection
Efficient, closed and scalable transfection for ex vivo cell and gene therapy applications -
4D-Nucleofector® Hardware Manual
Manual for next generation 4D-Nucleofector Core, X, Y, 96-well, and LV Unit Vers.1
-
4D-Nucleofector® LV Unit for Cell and Gene Therapy Applications – Benefits and How it Works
From this video learn how it works and its benefits for cell and gene therapy manufacturing. -
4D-Nucleofector® Platform - The Story Of
See how breakthrough Nucleofector® Technology innovations in transfection and electroporation culminate in the next generation 4D-Nucleofector® System.
Lonza GS Xceed™ Cells transfected in small or larger scale show comparable IgG4 titers
For a human IgG4 antibody, similar titers of about 100 µg/mL were achieved in small scale (100 µl) and large scale transfections (1 ml fixed cartridge or 10 mL in flow through LV cartridge) in a 6-day batch culture without any feeds. IgG titers were increased by factor 2.5 when using higher seeding densities (not shown here). Switching to a 14-day fed-batch culture led to titers > 1 mg/mL (not shown here).
Transfection of GFP mRNA into PBMCs
Fresh PBMCs (1x10⁸/mL) were transfected with GFP mRNA (20 µg/mL) using different Nucleofection® Vessels. For the fixed volume vessels (100 µL Nucleocuvette® Vessel and 1 mL Nucleocuvette® Cartridge), cells and mRNA for each sample were mixed separately, pipetted into the vessel and pulsed immediately. For the flow-through LV Nucleocuvette® Cartridge two feeding reservoirs were used to keep cells and mRNA separate as long as possible. Data are based on duplicates (experiment 1) or unicates (experiment 2).